BiotechTube
Home/Pipeline/Tumor Marker Portfolio (PSA, CA125, etc.)

Tumor Marker Portfolio (PSA, CA125, etc.)

Various Cancers

CommercialActive

Key Facts

Indication
Various Cancers
Phase
Commercial
Status
Active
Company
H.U. Group Holdings

About H.U. Group Holdings

H.U. Group Holdings is a leading integrated healthcare company in Japan, with a core business in clinical laboratory testing and the development, manufacturing, and sale of in-vitro diagnostics. Its strategic subsidiaries, SRL and Fujirebio, provide a comprehensive portfolio from routine testing to advanced cancer diagnostics and companion diagnostics. The company leverages its dual strength in testing services and IVD manufacturing to drive growth in precision medicine and global diagnostics markets.

View full company profile

Therapeutic Areas

OncologyNeurologyInfectious DiseaseGeneral Healthcare

Other Various Cancers Drugs

DrugCompanyPhase
RetifanlimabEli LillyPhase 2/3
Imfinzi (durvalumab)AstraZenecaApproved
Lynparza (olaparib)MerckCommercial
Oncology PortfolioPfizerPhase 1-3
PD-1 InhibitorAkesoPhase 2/3
Mitoxantrone LiposomeCSPC Pharmaceutical Group LimitedPhase 3
Biosimilar BevacizumabCiplaCommercial
Tazverik (tazemetostat)EisaiCommercial
Oncology GenericsAurobindo PharmaCommercial
Opdivo (nivolumab)Ono PharmaceuticalApproved
Oncology APIs (e.g., Sorafenib, Lenalidomide)Laurus LabsCommercial/Filed
Logic-gated Switch-DARPinsMolecular PartnersPreclinical